Issue 6, 2020

Tumor microenvironment responsive mesoporous silica nanoparticles for dual delivery of doxorubicin and chemodynamic therapy (CDT) agent

Abstract

Chemodynamic therapy is a new antitumor strategy triggered by transition metal as chemodynamic agent via the in situ catalytic Fenton reaction. Herein, we engineer a smart nanocarrier activated by tumor microenvironment-specific weak acidic pH and high glutathione conditions for chemo/chemodynamic processes. This unique architecture orderly consists of mesosilica-encapsulated doxorubicin, self-polymerization of polydopamine Fe3+ clathrate, further bonding the targeting polymer MnO2 disguised albumin–folic acid. Polydopamine and albumin as intelligent nanovalves shield doxorubicin from premature leaking. Folic acid improves the targeting capability for folate receptor (FR) overexpressing cancer cells. After intake of the nanocarrier by tumor cells, the nanocarrier nanovalves are first biodegraded by native glutathione and pH, enabling on-demand anticancer drug escape, and also generate and release Fe3+ and Mn2+ (reduced by MnO2via glutathione depletion). Subsequently, the ions interact with H2O2, generating highly toxic hydroxyl radicals (˙OH) via a Fenton-like reaction to enhance the anticancer cell efficacy. This result proves that the designed nanocarrier more likely devours into FR-positive cancer cells and illustrates a high intracellular ˙OH generation, leading to the desired specific killing efficacy. We believe this innovative strategy will exhibit a new avenue for the potential of accurate chemo/chemodynamic co-therapy in cancer cells.

Graphical abstract: Tumor microenvironment responsive mesoporous silica nanoparticles for dual delivery of doxorubicin and chemodynamic therapy (CDT) agent

Supplementary files

Article information

Article type
Paper
Submitted
30 Oct 2019
Accepted
08 Jan 2020
First published
16 Jan 2020

New J. Chem., 2020,44, 2578-2586

Tumor microenvironment responsive mesoporous silica nanoparticles for dual delivery of doxorubicin and chemodynamic therapy (CDT) agent

Y. Zhang, O. Eltayeb, Y. Meng, G. Zhang, Y. Zhang, S. Shuang and C. Dong, New J. Chem., 2020, 44, 2578 DOI: 10.1039/C9NJ05427H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements